---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027621"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-06-08T11:05:29+00:00"
generated_at: "2026-06-08T11:12:45.554253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tonix secures second GPO agreement for TONMYA, expanding commercial coverage to ~52M lives

## Summary
- Second GPO agreement effective June 1, 2026 adds ~17M US commercial lives (~10% of total).
- Total commercial coverage now ~52M lives (~29% of US commercial lives); first GPO covered ~35M from May 1.
- TONMYA covered under Medicaid in most states (~75M beneficiaries); Medicare discussions ongoing.
- TONMYA (cyclobenzaprine HCl sublingual tablets) approved by FDA Aug 2025 as first new fibromyalgia treatment in over 15 years.

## SEC filing metadata
- accession: 0001493152-26-027621
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-06-08T11:05:29+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000149315226027621/0001493152-26-027621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000149315226027621/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027621
- JSON: https://secwatch.observer/filing/0001493152-26-027621.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027621.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.